extended-release - Page 1 | CARLAT PUBLISHING

A Longer Acting Lorazepam

March 4, 2022

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report.

The straight facts on Loreev, a new extended-release formulation of lorazepam (Ativan).

“What About the Implant, Doc?” Appraising Various Formulations of Buprenorphine

August 6, 2020

Edmund S. Higgins, MD.

Edmund S. Higgins, MD. Clinical Associate Professor of Psychiatry and Family Medicine, MUSC, Charleston, SC. Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Buprenorphine can be administered via intravenous, transdermal, sublingual, buccal, and implanted formulations. We appraise the evidence for various formulations and suggest certain populations for which certain formulations may be a better choice.

Trazodone: The Forgotten Antidepressant

May 7, 2020

Eugene Rubin, MD

Eugene Rubin, MD Private practice, Bingham Farms, MI. Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Trazodone is rarely used as an antidepressant, and that’s a missed opportunity. It lacks the weight gain, sleep disruption, and sexual side effects that so many antidepressants cause. In this article are two important dosing tips that can make it work better.

Gabapentin Enacarbil XR Efficacy Less Than Expected for AUD

August 1, 2019

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This 2019 randomized, double-blind, placebo- controlled trial study casts doubt on using gabapentin enacarbil extended-release (GE-XR) (Horizant), an extended-release version of gabapentin, for treatment in patients with alcohol use disorder

FDA Approves Adhansia XR

June 11, 2019

Talia Puzantian, PharmD, BCPP and Joshua Feder, MD

Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this article we discuss a newly FDA-approved formulation for ADHD. Adhansia XR, is a new formulation of extended-release methylphenidate approved by the FDA for the treatment of ADHD in patients 6 years and older.